The persistence of γ-H2AX foci in cells hypersensitive to DNA damaging agents has prompted extensive research into the application of γ-H2AX as a biomarker to predict both tumor response and acute and delayed side effects in cancer patients receiving clinical radiotherapy and/or chemotherapy (2). This evidence concerns the gene H2AX and neoplasm.